AIM ImmunoTech (AIM) said Tuesday it has dosed the first new subject in phase 2 of a phase 1b/2 clinical trial evaluating the company's Ampligen and AstraZeneca's (AZN) Imfinzi as a potential combination to treat late-stage pancreatic cancer.
Phase 2 will also include various subjects who received the highest dose, AIM said.
The company said that up to 25 patients are expected to be enrolled in the study's phase 2.
AIM shares were down over 8% in recent trading.
Price: 0.12, Change: -0.01, Percent Change: -8.44
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.